Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Research context
Tekla Life Sciences Investors appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Financial Services
- Industry
- Asset Management
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Tekla Life Sciences Investors is currently in a long term uptrend where the price is trading 6.7% above its 200 day moving average.
From a valuation standpoint, the stock is 57.0% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 3.9.
Tekla Life Sciences Investors's total revenue rose by 65.9% to $2M since the same quarter in the previous year.
Its net income has increased by 196.2% to $30M since the same quarter in the previous year.
Based on the above factors, Tekla Life Sciences Investors gets an overall score of 4/5.